Recently, the use of nonselective β-or β 2 -blockers was advocated by clinical trials and studies, 7, 8 emphasizing the importance of β 2 -adrenergic signaling in heart failure. Although the effects of remodeling the β 1 /β 2 -adrenergic system on © 2015 American Heart Association, Inc. 
I
ncreased β-adrenergic sympathetic activity is a hallmark of heart failure and often leads to ventricular remodeling and impaired cardiac contractile function. Up to 50% of heart failure, mortality is sudden because of arrhythmias. β 1 or nonselective adrenergic blockers can reverse ventricular remodeling and reduce mortality in patients with heart failure. 1 Although the antiarrhythmic effect of β-blockers has long been recognized, 2 the underlying mechanism is incompletely understood. 3 To date, the effect of β-adrenergic signaling on electrophysiology and arrhythmias has never been studied in tissue preparations from failing and nonfailing human hearts.
β-Adrenergic stimulation can lead to sarcoplasmic reticulum Ca overload, spontaneous sarcoplasmic reticulum Ca release, and delayed afterdepolarization (DAD). 4 In addition, β-receptors regulate multiple ion channels via the cAMP/ protein kinase A (cAMP/PKA) cascade, which is electrogenic and potentially arrhythmogenic. However, cellular studies cannot fully explain arrhythmogenesis and arrhythmia maintenance at the tissue level. Potential arrhythmogenic substrates because of β-stimulation include abnormal impulse conduction, altered repolarization dynamics, and transmural heterogeneity in repolarization. The human ventricular free wall is composed of 3 layers: subendocardium, midmyocardium, and subepicardium. These layers possess different intrinsic electric properties that account for activation delays and synchronized ventricular repolarization. 5 In heart failure, these properties are altered because of molecular and structural remodeling, including remodeling of β-adrenergic receptors (ARs), and may set the stage for triggered arrhythmias, as seen in patients with heart failure.
Two dominant subtypes of β-AR are β 1 -and β 2 -AR. Although β 1 -AR predominates in the human myocardium, β 2 -AR is equally important because of its more efficient adenylyl cyclase coupling and endogenous role in cardiac regulation. 6 contractility have been studied in human trabeculae, 9 the effect of β 1 /β 2 -remodeling on electrophysiology and arrhythmogenesis in the left ventricular (LV) wall of the human failing heart is unknown.
We hypothesized that in end-stage heart failure, β 1 -and β 2 -adrenergic signaling are differentially remodeled and have different effects on arrhythmogenesis. To compare β 1 -and β 2 -selective adrenergic effects, we assessed excitationcontraction coupling using dual optical mapping of action potential (AP) and [Ca 2+ ] i transients (CaT) in LV wedge preparations from human failing and donor hearts. Our data indicate that β 2 -stimulation, in contrast to β 1 -stimulation, induces transmural heterogeneity in repolarization and sets the stage for arrhythmias. Furthermore, we show that β 2 -AR signaling enables the formation of DADs by increasing the difference between CaT duration (CaD) and AP duration (APD), suggesting an underlying mechanism of triggered arrhythmias, such as those observed in patients with heart failure.
Material and Methods

Experimental Protocol
Procurement and use of human myocardium were approved by the Institutional Review Board of Washington University School of Medicine. Nonischemic end-stage failing human hearts (n=8) were procured at the time of transplantation at Barnes-Jewish Hospital. Nonfailing donor hearts (n=8) were procured at Mid-America Transplant Services (St Louis, MO) and were used as controls. The clinical data of patients are shown in Table I in the Data Supplement.
The arterially perfused LV wedge preparations ( Figure I in the Data Supplement) and dual optical mapping were described previously 10, 11 and in Methods in the Data Supplement. Fluorescent probes, RH237 and Rhod-2AM, were used for AP and CaT, respectively. We used selective β 2 -AR agonist procaterol (1 μmol/L), 12 selective β 1 -AR agonist xamoterol (1 μmol/L), 13 and nonspecific β-AR agonist isoproterenol (100 nmol/L; Tocris Bioscience, Ellisville, MO; Figure  II in the Data Supplement). The agonists were applied at saturating concentrations for maximum effective activation of the receptors. 12, 13 Complete washout evaluated by the recovery of conduction velocity (CV), APD, and CaD was applied between xamoterol and procaterol.
Statistical Analysis
For studies in which baseline and β-stimulation measures were compared, we conducted analyses with a mixed random effects repeated measures model with group, time, and group-by-time interaction as fixed effects. For each analysis, several covariance structures were fit, and the fit with the smallest Bayesian Information Criteria score was used, which was the Toeplitz matrix structure. For experiments in which transmural layers were analyzed separately, we used a mixed random effects split-plot study design to account for layers having different degrees of freedom relative to the group. Post hoc t tests were then performed by Bonferroni correction. We considered P<0.05/(number of pairwise tests) to be statistically significant.
In Methods in the Data Supplement, we provide detailed data analysis and describe experimental protocols and methods, including Western blot, quantitative polymerase chain reaction, and immunofluorescence.
Results
Effects of β 2 -Versus β 1 -AR Stimulation on Arrhythmia Substrates in Heart Failure
Effects of β 2 -AR Stimulation on CV We quantified anisotropy as the ratio between longitudinal conduction velocity (CV L )/transverse conduction velocity (CV T ; Figure 1 ). 14 In both donor and failing hearts, CV T did not demonstrate a physiologically significant difference after β 1 -or β 2 -stimulation, although there was a statistically significant difference for β 2 -stimulation in failure ( Figure 1C and 1D). Both β 1 -and β 2 -agonists dramatically increased CV L in donor hearts. In failing hearts, only β 2 , but not β 1 , agonist increased CV L ( Figure 1E and 1F) . The quantitative analysis of velocity changes is shown in Figure III in the Data Supplement. Accordingly, anisotropy decreased with β 1 -stimulation and increased with β 2 -stimulation in failing hearts; however, in donor hearts, only conduction anisotropy is increased significantly during β 2 -stimulation ( Figure 1G and 1H) .
-Stimulation Increased Transmural Heterogeneity of Repolarization in Failing Hearts
To assess the effect of β-stimulation on repolarization, we quantified APD at 80% of repolarization in the subendocardium (endo), midmyocardium (mid), and subepicardium (epi; Figure 2 ). Classification of all layers is shown in Figure II in the Data Supplement. As previous studies have also shown, 15 we determined that APD in failing hearts, measured at different pacing rates in the absence or presence of β-stimulation, is significantly longer than APD in donor hearts ( Figure 2B ). Both β-agonists shortened APD in both groups. However, for the different layers, the agonists reduced APD to varying degrees ( Figure 2C ; Table II in the Data Supplement). This layer-dependent APD reduction increased the APD difference between endocardium and epicardium (APD 80endo −APD 80epi ) dramatically more in failing hearts than in donor hearts ( Figure 2D ).
WHAT IS KNOWN
• Excessive β-adrenergic stimulation is a hallmark of heart failure, which is associated with ventricular arrhythmias, a major source of death.
• However, the arrhythmogenic mechanisms of β-adrenergic signaling have never been studied in the human failing and nonfailing left ventricle.
WHAT THE STUDY ADDS
• In this study, we investigated the arrhythmogenic substrates resulting from β 1 -and β 2 -adrenergic stimulation during end-stage human heart failure and found that β 2 -stimulation, but not β 1 -stimulation, increases arrhythmia vulnerability through effects on both arrhythmogenic triggers and substrates.
• The findings suggest that targeting β 2 -adrenergic pathway may be more effective in treating and preventing arrhythmogenesis in heart failure than traditional β 1 -selective blockers.
We quantified the layer-dependent APD reduction (ΔAPD) at 1 Hz pacing in response to both β-agonists as the difference of APD values between baseline and in the presence of β-agonists ( Figure 3A ). ΔAPD maps revealed that β 1 -and β 2 -stimulation each resulted in different spatial patterns of APD reduction ( Figure 3B ).
In donor hearts, β 2 -agonist stimulation caused decreasing ΔAPDs (increasing reductions in APD) from the epicardium toward the endocardium. The opposite is seen in failing hearts, where β 2 -agonist treatment caused increasing ΔAPDs (decreasing reductions in APD) from the endocardium to the epicardium ( Figure 3C ). Taken together, the ΔAPD effect sizes between donor and failing hearts were greatest at the epicardium and decreased toward the endocardium. Strongly significant group-layer interactions for ΔAPD values (P<0.0001) highlight the differences in effect sizes between donor and failing hearts ( Figure 3C ). In failing hearts, the average APD reduction caused by β 2 -agonist in the transmural wall is greater than that in donor hearts. This suggests that the β 2 -AR pathway is sensitized in heart failure. β 1 -Agonist treatment produced APD reductions that were most pronounced in the endocardium and decreased toward the epicardium of donor hearts. In failing hearts, a modest and uniform APD reduction was observed. In donor hearts, β 1 -agonist induced a significant APD reduction in all layers. This demonstrates that the β 1 -AR pathway is desensitized in failing hearts ( Figure 3D ).
We aimed to determine the molecular mechanism underlying the layer-dependency of β 2 -stimulation by quantifying β 2 -AR protein expression. In contrast with previous findings, Unlike β 1 -AR, which couples only to G s , β 2 -AR can couple either to G s or to inhibitory G-protein (G i ). 15 Phosphorylation of β 2 -AR by PKA can switch its coupling from G s to G i . 17 Therefore, we assessed β 2 -AR phosphorylation at PKAphosphorylation site Ser345/Ser346 18 and found β 2 -AR phosphorylation was significantly lower in failing than that in donor hearts ( Figure 3F ), suggesting greater coupling to G s in failure.
Effect of β 2 -AR Stimulation on CaD Shortening
We recorded CaT simultaneously with AP to generate CaD maps ( Figure 4A and 4B) . CaD values at 80% of Ca relaxation are shown in Figure IV in the Data Supplement. CaD shortening (ΔCaD) was quantified to evaluate the effects of β-stimulation on Ca reuptake. β 1 -Agonist treatment induced significantly greater CaD reductions in donor than in failing hearts across the transmural wall ( Figure 4D ; the effect size between donor and failing hearts was transmurally homogeneous, as the group effect was strongly significant (P=0.0007), whereas the group-layer interaction was not significant (P=0.66). In contrast, β 2 -agonist treatment shortened CaD to a similar degree in both donor and failing hearts ( Figure 4C ). Interestingly, stimulation with the β 2 -agonist did not induce similar transmural spatial differences as those observed with APD reduction.
Transmural Gradient of CaD-APD
The CaD-APD is a measure of the period during which the intracellular calcium concentration ([Ca 2+ ] i ) remains at a high level after the membrane has been completely repolarized ( Figure 4E ). Prolongation of this period, defined as Δ(CaD-APD)=(CaD-APD) stimulation β −(CaD-APD) baseline , could lead to a window where the [Ca 2+ ] i is higher after β-stimulation than at baseline (green arrows in Figure 4E ) during the period of complete membrane repolarization. In this vulnerable window, DADs may occur because of inward currents from the Na-Ca exchanger (NCX) while it extrudes Ca
2+
. In failing hearts, we observed prolongation of the Δ(CaD-APD) after β 2 -stimulation in the epicardium (−42.8±10.7 ms for donor versus 13.6±6.9 ms for failing; P=0.003) and midmyocardium (−32.0±10.1 ms for donor versus 7.1±7.2 ms for failing; P=0.0074), but not in the endocardium (−23.1±8.0 ms for donor versus −31.6±12.1 ms for failing; P=0.53), where negative values indicates that CaD-APD value after stimulation is shorter than baseline condition. In donor hearts, prolongation of Δ(CaD-APD) after β 2 -stimulation was not observed (Figure 4F) . Also, there were no significant differences in transmural Δ(CaD-APD)s in either donor or failing hearts after β 1 -stimulation ( Figure 4G ).
β 2 -AR Stimulation Altered CaT Morphology
To evaluate changes in CaT morphology, we quantified the CaD 30 /CaD 80 ratio. 11 We observed that the ratio is greater at baseline in failing hearts than in donor hearts throughout the transmural wall, as previous findings have also shown 15 ( Figure 5A ). Treating with β 2 -agonist equalized the ratio (donor versus failing, 0.55±0.02 versus 0.55±0.01; ns after β 2 -stimulation and 0.52±0.015 versus 0.59±0.009; P=0.003 at baseline), which indicates a change in CaT morphology ( Figure 5B and 5E ). Although the ratio in failing hearts was still greater than in donor hearts after treatment with the β 1 -agonist, transmural heterogeneity was eliminated in both groups ( Figure 5C and 5F); this is demonstrated by a strongly significant group-layer interaction at baseline (P<0.0001), but the absence of a significant group-layer interaction after treatment with β 1 -agonist (P=0.076).
We analyzed Ca 2+ release and extrusion to determine the period in which β 2 -stimulation causes changes in CaT morphology. We did not observe a difference in Ca 2+ release when evaluating the rise time of CaT ( Figure V in Figure 5G ). However, the Ca 2+ decay constant was similar before and after β 2 -stimulation in failing hearts ( Figure 5H ), which suggests that abrogation of β 2 regulation of Ca 2+ handling occurred mainly during the slow Ca 2+ reuptake phase.
β-AR Stimulation Is Necessary for Ectopic Activity in Human Heart Failure
We counted premature ventricular contractions (PVCs) during 8 minutes of pacing (4 minutes of 0.5 Hz and 4 minutes of 0.67 Hz) and automaticity after pacing. We did not observe spontaneous automaticity or PVCs under any condition in donor hearts. In contrast, failing hearts exhibited both ectopic PVCs and automaticity in response to β-stimulation. Multiple types of PVCs were observed after β 2 -stimulation. Figure 6A shows automaticity and PVCs with different morphologies originating from different locations recorded after β 2 -stimulation in failing hearts. PVC#1 represents a type of irregularly occurring PVC with small amplitude and slow upstroke that propagated through a limited area, as circled, before being terminated. According to the AP signal amplitude map, these PVCs originated from the midmyocardium. PVC#2 represents another type of PVCs with greater amplitude and fast upstroke that can propagate through the transmural surface. This type of PVC originated from the endocardium ( Figure 6A ). Next, we analyzed the underlying mechanisms and involvement of calcium overload in these 2 types of PVCs (#1 and #2). We used AP-CaT delay map to measure the time difference between AP activation and Ca release. Figure 6B shows a PVC#1 where the Ca release occurred before AP upstroke, which suggests that it was triggered by Ca release. Thus, the mechanism responsible for PVC#1 may be a Ca-driven process enhanced by β 2 -stimulation. In all hearts, Ca-driven PVCs only originated from the subepicardium and midmyocardium ( Figure 7B ), which were the transmural regions with prolonged CaD-APD.
PVC#2 shared the same origin with a series of regular beats of enhanced automaticity. This automaticity originated from the endocardium with a rate of 33 beats per minute and was eliminated by rapid delivery of Lugol's solution to the subendocardial surface, suggesting that these events are because of the Purkinje fiber automaticity. 19 To test this hypothesis, we determined the presence of the Purkinje fiber marker connexin 40 by immunofluorescence. 20 Figure 6D (top-right) shows that the tissue from where the regular beats originated has high expression of connexin 40 at the intercalated disk, further implicating that Purkinje fiber automaticity underlies the observed events.
β-AR Stimulation Increased Occurrence of Spontaneous PVCs and Rapid Pacing-Induced Ventricular Tachycardia in Failing Hearts
To confirm the described mechanisms of automaticity and ectopy, we used real-time pseudo-ECG and monophasic AP recordings to measure the occurrences of PVCs and pacinginduced ventricular tachycardia (VT; Figure 7A ). The number of PVCs and VTs dramatically increased after β-AR stimulation in failing hearts, but neither could be induced in donor hearts ( Figure 7C-7E) . Both β 1 -and β 2 -stimulation induced more automaticity and PVCs in the endocardium when compared with other regions, which mainly originated in the Purkinje fibers. Unlike β 1 -agonist, which induced automaticity in the Purkinje fibers only, β 2 -agonist also induced PVCs in epicardium and midmyocardium in addition to endocardium, among which >44% were Ca-mediated. No Ca-driven PVCs were observed during β 1 -stimulation ( Figure 7B ).
Discussion
Our data show, for the first time, a differential role of β 1 -and β 2 -AR pathways in arrhythmogenesis in human heart failure. We show that in failing hearts, β 1 -and β 2 -stimulation provoke automaticity and PVCs through ≥2 mechanisms. Both β-ARs increase automaticity in Purkinje fibers, but only β 2 -AR stimulation causes Ca-driven PVCs. β 2 -Stimulation further enhances arrhythmogenic substrates via CV regulation, spatially heterogeneous repolarization, and CaD. Importantly, β 2 -stimulation increased the transmural difference between CaD and APD, which facilitated the formation of DAD (summarized in Figure 8B ).
Arrhythmogenesis Because of β 2 -and β 1 -Stimulation During End-Stage Heart Failure
Desensitization of β 1 -AR and preserved effects of β 2 -AR have been previously reported in gene/protein expression, 16 and cardiac mechanics 9 in human endocardial biopsies from patients with heart failure. We mapped the entire transmural LV and found sensitization of β 2 -AR at the subendocardium and midmyocardium of failing hearts. Moreover, in contrast to attenuated β 1 -regulation in failing hearts, β 2 -regulation is not only sensitized but also remodeled at the molecular and tissue level. This remodeling develops an arrhythmic substrate involving conduction, repolarization, and Ca handling in end-stage heart failure. Although β 2 -stimulation affected CV similarly in failing and donor hearts, the average anisotropy was increased only in failing hearts. Because of this increase, the impulse propagates slowly in the transverse direction but rapidly in the longitudinal direction, which may lead to conduction block, 21 whereas β 1 -stimulation lowers such vulnerability by decreasing the anisotropy. In addition, β 2 -stimulation (but not β 1 -stimulation) induced remodeling of repolarization in time and space domains, such as altered refractoriness and increased transmural heterogeneity, which would widen the vulnerability window and facilitate unidirectional block and reentrant arrhythmias. 22 The additional arrhythmogenicity resulting from β 2 -stimulation in the human failing myocardium provides mechanism for recent studies advocating the use of nonselective β-blockers or β 2 -specific blockers for heart failure.
7,8
Switching of β 2 -AR Coupling From G i to G s in Failing Hearts β 2 -AR stimulation resulted in significant reduction of APD across the transmural surface in failing hearts when compared with that in donor hearts, which suggests sensitization of β 2 -AR in heart failure. This effect may result from a β 2 -AR coupling switch from G i to G s proteins because of β 2 -AR phosphorylation by PKA, which is also activated by G s. 17 We observed significantly reduced β 2 -AR phosphorylation in failing hearts, which suggests that β 2 -ARs switch from G i to G s in heart failure. The switch from the protective G i -dependent negative feedback control system to an unstable G s -dependent positive feedback control system was rendered via remodeling of β 2 -AR signaling ( Figure 8A ) in heart failure. Therefore, β 2 -AR could enhance its control of excitation-contraction coupling through switching from G i to G s , as evident from enhanced ΔAPD in failing hearts. Our observations are in agreement with studies by Gong et al. 23 Their data showed a negative inotropic effect in failing human ventricular cardiomyocytes after application of β 2 -AR antagonist ICI118551. In contrast, cardiomyocytes from nonfailing hearts showed no significant decreased inotropic effect in the presence of β 2 -AR antagonist. These data further support our conclusion that, in heart failure, a greater proportion of β 2 -AR couples with G s . Furthermore, β 2 -AR overexpression has a negative inotropic effect after treatment with ICI118551 in mouse models. 24 An increased proportion of β 2 -AR-G s coupling was reported in this transgenic mouse model, 24 which, along with previously described work in human hearts, 23 lends support to our theory.
G i to G s Switch Abrogates Increase of NCX Activity Caused by β 2 -Stimulation
In this study, we established that abrogation of β 2 -regulation during the late phase of Ca extrusion accounted for CaT ] i transients (CaT) delay map and found to share the same location with PVC#1. Activation times from 2 locations were labeled: PVC origination (point #1 and 3 on AP and CaT activation map, respectively) and an adjacent location (#2 and 4). Activation time of 3 (CaT, 22 ms) is earlier than 1 (AP, 26 ms), and this difference is reversed shortly after AP propagated: activation time of 2 (AP, 28 ms) is before 4 (CaT, 30 ms). C, Enhanced automaticity shared the same location as PVC#2. D, Immunofluorescence staining of connexin 40 and 4',6-diamidino-2-phenylindole. Connexin 40 staining was observed in coronary vascular endothelium (top-left) and endocardium (middle-right). The staining is negative in epicardium (bottom-left). The region of enhanced automaticity (small yellow box) expressed connexin 40 (top-right). Intramural tract branch of Purkinje fibers penetrating into myocardium was also observed (bottom-right). AP indicates action potential; endo, subendocardium; epi, subepicardium; FOV, field of view; MAP, monophasic AP; and mid, midmyocardium. morphological change in heart failure. Between the major proteins (SERCA [sarco/endoplasmic reticulum Ca
2+
-ATPase] and NCX) that determine Ca extrusion, NCX has been recognized to contribute more during CaT late phase 25 because of membrane potential being lower than the equilibrium potential of NCX (E Na/Ca ). 26 When NCX is overexpressed, β 2 -stimulation upregulates its activity through β 2 -AR coupling to G i protein. 27 However, this increase is not supported by our result ( Figure 5G ). Given that NCX is overexpressed in heart failure (Figure VI in the Data Supplement), we postulate that reduced β 2 -regulation may be because of decreased β 2 -AR-G i coupling.
Transmural Remodeling of β 2 -AR Regulation and DAD
In contrast to APD regulation, β 2 -AR system neither enhanced Ca handling in failing hearts nor increased transmural CaD heterogeneity in either group. This disparity resulted in increased CaD−APD difference, which exacerbated DAD initiation. Here, we show DAD triggered PVCs associated with Ca release preceding AP upstroke in failing human LV myocardium. Interestingly, such calcium-mediated PVCs were only observed during β 2 -stimulation. PVCs were localized at the epicardium and midmyocardium, where (CaD-APD) is prolonged. In heart failure, given NCX activity has not been further augmented by β 2 -stimulation because of receptor uncoupling from G i , the substrate (CaD-APD) could play a crucial role in DAD initiation ( Figure 8A and 8B) . In contrast, β 1 -stimulation did not provoke DADs in failing hearts.
Purkinje Fibers Are Responsible for the Majority of Automaticity During β-Stimulation in Heart Failure
Low-frequency PVCs in normal hearts are considered benign, but frequent PVCs in failing hearts are associated with LV dysfunction. 28 In our study, the majority of PVCs originated from the connexin 40-positive subendocardium. This suggests that PVCs evoked by β 1 -and β 2 -AR stimulation arise in the Purkinje fibers in heart failure. Furthermore, it indicates that both subtypes may preserve the functional state of Purkinje fibers, different from that of working myocytes. Additionally, β 2 -stimulation also evokes DAD-induced triggered activity in the subepicardium and midmyocardium. Therefore, only β 2 -stimulation, not β 1 -stimulation, leads to increased arrhythmia vulnerability by facilitating arrhythmogenic triggers and substrates. This specificity suggests that nonselective or β 2 -selective blockers may be more effective in treating and preventing arrhythmogenesis in heart failure than β 1 -selective blockers.
Limitations
A possible limitation of our study is our use of specific β 1 -and β 2 -agonists instead of a commonly used nonspecific agonist combined with isoform-specific antagonists. We selected isoform-specific agonists procaterol (1 μmol/L) 12 and xamoterol (1 μmol/L) 13 because of their established specificity in the settings of heart failure. Furthermore, it was not possible to do a dose response investigation because of the limited number of human hearts and limited time available for experiments. We decided not to use an alternative approach based on isoproterenol combined with β 1 -and β 2 -blockers because we wanted to investigate the 2 types of receptors in the same heart, with access to a limited number of hearts. We acknowledge that the lack of dose response data limits our ability to compare the relative contributions of β 1 and β 2 to excitation-contraction coupling. Therefore, our comparisons were only between donor and failing hearts. Furthermore, we confirmed the selectivity of β 1 -agonist xamoterol, which had dramatic stimulation effects 
